Search Medical Condition
Please enter condition
Please choose location from dropdown

Mexico D.F.C.P., Mexico Clinical Trials

A listing of Mexico D.F.C.P., Mexico clinical trials actively recruiting patients volunteers.

RESULTS

Found (318) clinical trials

Subcutaneous Nitroglycerin to Facilitate Trans-radial Access.

Unlike femoral access, the trans-radial approach to coronary angiography requires a greater learning curve for the inexperienced interventionist, and demands a greater technical challenge than the femoral approach, which leads to a high incidence of failures and complications, mainly in the initial stages of their formation. Some explanations for procedural ...

Phase

1.26 miles

Learn More »

Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate

The purpose of this study is to provide access to palbociclib in Mexico and in selected Latin American countries before it becomes commercially available to patients with HR positive/HER2-negative ABC who are appropriate candidates for letrozole therapy.

Phase

2.07 miles

Learn More »

Comparison High-Density Silicone Oils in Retinal Detachment

Five to 10% of retinal detachments progressed to proliferative vitreoretinopathy (PVR), the common more cause of surgical failure of retina detachment. Despite the use of internal tamponades, the treatment of retinal detachments due to a progressed proliferative vitreoretinopathy (PVR) is still a problem. At present, conventional silicone oil, having a ...

Phase

2.46 miles

Learn More »

Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome

Purpose:Retinopathy of prematurity (ROP) continues tobe a major cause of blindness in children. Although ablation of the retina with laser or cryotherapy reduces the incidence of blindness by suppressing the neovascular phase of ROP the visual outcomes after treatment are often poor. Vascular endothelial growth factor(VEGF) has an important role ...

Phase

2.48 miles

Learn More »

Intravitreal Bevacizumab for Age-Related Macular Degeneration

The neovascular age related macular degeneration(AMD) is a important cause of legal blindness in adults older than 50 years. Currently the treatment is photodynamic therapy that offer stabilization and limited visual improvement after 2 years of therapy. Bevacizumab has been reported effective used as intravenous injection for AMD. But serious ...

Phase

2.48 miles

Learn More »

Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration

The neovascular age related macular degeneration(AMD) is a important cause of legal blindness in adults older than 50 years. Currently the treatment is photodynamic therapy that offer stabilization and limited visual improvement after 2 years of therapy. Bevacizumab has been reported effective used as intravenous injection for AMD. But serious ...

Phase

2.48 miles

Learn More »

Intravitreal Bevacizumab Vs Photocoagulation for Proliferative Diabetic Retinopathy

The current gold standard for the treatment of proliferative diabetic retinopathy is panretinal photocoagulation. However, it is a treatment that results in significant discomfort to the patient, causes reduction of visual acuity and visual field impairment. Intravitreal bevacizumab is a novel treatment that reduces intraocular VEGF concentration and therefore inhibits ...

Phase

2.48 miles

Learn More »

Bevacizumab and Retinal Vascular Occlusions

To evaluate the effects of Intravitreal Bevacizumab in macular edema in retinal vascular occlusion.

Phase

2.48 miles

Learn More »

Pressurized PPV 23GA Vitrectomy in Complicated Diabetic Tractional Retinal Detachment

To investigate the feasibility and advantages of using pressurized perfluorocarbon liquid (PCL) perfusion to remove vitreous during suction-cutting 23 GA vitrectomy using a dual, dynamic drive (3D)technology, in complicated retinal detachment surgeries.

Phase

2.48 miles

Learn More »

Effect of Avastin in Juxtafoveal Telangiectasias

After diagnose Yuxtafoveal telangiectasias secondary to Branch Retinal Vein Occlusion and with Idiopathic Ethiology by clinical signs and Fluorescein angiogram (FA)findings we treated patients with Intravitreal Injection of Bevacizumab (2.5mg/0.1ml). We performed a complete ophthalmological evaluation and at baseline and follow-up (1 and 3 months) we evaluate ETDRS Best Corrected ...

Phase

2.48 miles

Learn More »